May 30, 2017 06:59 AM EDT
Pharma

J&J buys in­to Pro­tag­o­nist’s next-gen pep­tide sto­ry with $50M up­front and $940M in mile­stones

John Carroll

Editor & Founder

J&J’s ven­ture arm par­tic­i­pat­ed in the start­up rounds for Pro­tag­o­nist Ther­a­peu­tics’ ear­ly de­vel­op­ment, fu­el­ing its work on a new group of oral pep­tide ther­a­pies …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

Lasker Award goes to three sci­en­tists who pi­o­neered re­search be­hind GLP-1 drugs

Edge­wise’s stock surges as heart drug pass­es ear­ly safe­ty test

Stem cell start­up spun out of George Church’s lab rais­es $75M

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times